Page last updated: 2024-10-27

fluoxetine and Anxiety, Separation

fluoxetine has been researched along with Anxiety, Separation in 10 studies

Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.

Anxiety, Separation: Anxiety experienced by an individual upon separation from a person or object of particular significance to the individual.

Research Excerpts

ExcerptRelevanceReference
"To assess the efficacy of fluoxetine for the long-term treatment of children and adolescents with anxiety disorders, including generalized anxiety disorder, separation anxiety disorder, and/or social phobia."9.11Fluoxetine for the treatment of childhood anxiety disorders: open-label, long-term extension to a controlled trial. ( Axelson, D; Birmaher, B; Brent, D; Bridge, J; Clark, DB; Ehmann, M; Kalas, C; Monk, K; Muthen, B; Wood, DS, 2005)
"An open-label pilot study examined fluoxetine treatment in 16 outpatients (9-18 years old) with mixed anxiety disorders."9.08Open fluoxetine treatment of mixed anxiety disorders in children and adolescents. ( Asche, BK; Dummit, ES; Fairbanks, JM; Kentgen, LM; Klein, RG; Martin, J; Pine, DS; Tancer, NK, 1997)
"To assess the efficacy of fluoxetine for the long-term treatment of children and adolescents with anxiety disorders, including generalized anxiety disorder, separation anxiety disorder, and/or social phobia."5.11Fluoxetine for the treatment of childhood anxiety disorders: open-label, long-term extension to a controlled trial. ( Axelson, D; Birmaher, B; Brent, D; Bridge, J; Clark, DB; Ehmann, M; Kalas, C; Monk, K; Muthen, B; Wood, DS, 2005)
"An open-label pilot study examined fluoxetine treatment in 16 outpatients (9-18 years old) with mixed anxiety disorders."5.08Open fluoxetine treatment of mixed anxiety disorders in children and adolescents. ( Asche, BK; Dummit, ES; Fairbanks, JM; Kentgen, LM; Klein, RG; Martin, J; Pine, DS; Tancer, NK, 1997)
"Canine separation anxiety is a common behavioral problem presented to veterinarians."2.73Effects of reconcile (fluoxetine) chewable tablets plus behavior management for canine separation anxiety. ( Ciribassi, JJ; Clark, TP; Douglass, G; Horwitz, D; Houpt, KA; Kroll, TL; Landsberg, GM; Luescher, A; Moffat, KS; Reisner, IR; Robertson-Plouch, C; Simpson, BS; Veenhuizen, MF; Zimmerman, A, 2007)

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's5 (50.00)18.2507
2000's4 (40.00)29.6817
2010's1 (10.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Karagiannis, CI1
Burman, OH1
Mills, DS1
Clark, DB1
Birmaher, B1
Axelson, D1
Monk, K1
Kalas, C1
Ehmann, M1
Bridge, J1
Wood, DS1
Muthen, B1
Brent, D1
Bhansali, P1
Dunning, J1
Singer, SE1
David, L1
Schmauss, C1
Simpson, BS1
Landsberg, GM1
Reisner, IR1
Ciribassi, JJ1
Horwitz, D1
Houpt, KA1
Kroll, TL1
Luescher, A1
Moffat, KS1
Douglass, G1
Robertson-Plouch, C1
Veenhuizen, MF1
Zimmerman, A1
Clark, TP1
Campbell, M1
Cueva, JE1
Fairbanks, JM1
Pine, DS1
Tancer, NK1
Dummit, ES1
Kentgen, LM1
Martin, J1
Asche, BK1
Klein, RG1
Clarke, AS2
Kraemer, GW2
Kupfer, DJ1
Ebert, MH1
Schmidt, DE1
McKinney, WT1
Lee, HJ1
Kim, JW1
Yim, SV1
Kim, MJ1
Kim, SA1
Kim, YJ1
Kim, CJ1
Chung, JH1
Koizumi, H1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Vilazodone for Separation Anxiety Disorder[NCT01999920]Phase 424 participants (Actual)Interventional2013-12-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline Hamilton Rating Scale for Depression 17-item Total Score

This standard scale will be used to assess severity of depression, looking at change in total score from baseline to week 12, rating severity of depression on a scale from 0 (least depression) to 50 (greatest depression). (NCT01999920)
Timeframe: Up to 12 weeks

Interventionunits on a scale (Mean)
Vilazodone3.7
Placebo8.4

Change From Baseline in Quality of Life Enjoyment & Satisfaction Questionnaire

Measure Description: (10 min) Quality of Life Enjoyment & Satisfaction Questionnaire (Q-LES-Q, Endicott et al, 1993): self-rated assessment of quality of life. 16 items related to life quality, each rated on a score of 1 (very poor) to 5 (very good), with a minimum total score of 16, and a maximum total score of 80. (NCT01999920)
Timeframe: Up to 12 weeks

Interventionunits on a scale (Mean)
Vilazodone68.9
Placebo47.8

Change From Baseline on Adult Separation Anxiety - 27 Scale

Measure Description: (15 min) Adult Separation Anxiety - 27 Scale 27 items pertaining to adult separation anxiety, each self-rated on a four-point scale, 0=best, 3=worse. Minimum Total Score=0 (better); Maximum Total Score = 81 (worse) (NCT01999920)
Timeframe: Up to 12 weeks

Interventionunits on a scale (Mean)
Vilazodone14.4
Placebo40.6

Change From Baseline on Structured Clinical Interview for Separation Anxiety Disorder

The Structured Clinical Interview for Separation Anxiety Disorder was modified for DSM-5. The eight separation anxiety disorder criteria are rated for both childhood (rated at baseline only) and past week time frames, scored as 0 (not at all), 1 (sometimes), 2 (often) or ? (don't recall). In keeping with the DSM-5 guidelines, endorsement of three or more of the eight criterion symptoms (symptoms rated as '2' or 'often') is used as a threshold to determine categorical (yes/no) diagnosis of separation anxiety disorder. Scores on each of the eight items are also summed to produce a continuous measure of separation anxiety symptoms experienced during childhood and adulthood (range for each scale=0-16). (NCT01999920)
Timeframe: Baseline and week 12

Interventionunits on a scale (Mean)
Vilazodone3.1
Placebo5.0

Clinical Global Impression-Improvement Scale

"Clinical Global Impression-Improvement Scale rating at week 12 A quickly administered and widely used observer rating, with ratings from 1 (very much improved) to 7 (very much worse). Responder is a score of 1 or 2." (NCT01999920)
Timeframe: Up to 12 weeks

InterventionParticipants (Count of Participants)
Vilazodone7
Placebo4

Change From Baseline in Attachment Style Questionnaire Score

Measure Description: (15 min) Attachment Style Questionnaire (Feeney at al., 1994) 40 items relating to quality of adult relationships. Questionnaire includes questions concerning Confidence (8 items, minimum score=8, maximum score=48), Discomfort (10 items, minimum score=10, maximum score=60), Relationships as Secondary (7 items, minimum score=7, maximum score=42), Need for Approval (7 items, minimum score=7, maximum score =42), and Preoccupation with Relationships (8 items, minimum score = 8, maximum score=48), each self-rated on a six-point scale, each self-rated from 1 (totally disagree) to 6 (totally agree). (NCT01999920)
Timeframe: Up to 12 weeks

,
Interventionunits on a scale (Mean)
ConfidenceDiscomfort with ClosenessRelationships as SecondaryNeed for ApprovalPreoccupation with Relationships
Placebo26.942.320.723.632.1
Vilazodone32.335.616.320.630.0

Reviews

1 review available for fluoxetine and Anxiety, Separation

ArticleYear
Psychopharmacology in child and adolescent psychiatry: a review of the past seven years. Part II.
    Journal of the American Academy of Child and Adolescent Psychiatry, 1995, Volume: 34, Issue:10

    Topics: Adolescent; Alprazolam; Anticonvulsants; Antipsychotic Agents; Anxiety, Separation; Bipolar Disorder

1995

Trials

4 trials available for fluoxetine and Anxiety, Separation

ArticleYear
Dogs with separation-related problems show a "less pessimistic" cognitive bias during treatment with fluoxetine (Reconcileā„¢) and a behaviour modification plan.
    BMC veterinary research, 2015, Mar-28, Volume: 11

    Topics: Administration, Oral; Animals; Anxiety, Separation; Behavior, Animal; Discrimination, Psychological;

2015
Fluoxetine for the treatment of childhood anxiety disorders: open-label, long-term extension to a controlled trial.
    Journal of the American Academy of Child and Adolescent Psychiatry, 2005, Volume: 44, Issue:12

    Topics: Adolescent; Anxiety Disorders; Anxiety, Separation; Child; Female; Fluoxetine; Follow-Up Studies; Hu

2005
Effects of reconcile (fluoxetine) chewable tablets plus behavior management for canine separation anxiety.
    Veterinary therapeutics : research in applied veterinary medicine, 2007,Spring, Volume: 8, Issue:1

    Topics: Administration, Oral; Animals; Antidepressive Agents, Second-Generation; Anxiety, Separation; Behavi

2007
Open fluoxetine treatment of mixed anxiety disorders in children and adolescents.
    Journal of child and adolescent psychopharmacology, 1997,Spring, Volume: 7, Issue:1

    Topics: Adolescent; Anti-Anxiety Agents; Anxiety Disorders; Anxiety, Separation; Child; Female; Fluoxetine;

1997

Other Studies

5 other studies available for fluoxetine and Anxiety, Separation

ArticleYear
Early life stress alters adult serotonin 2C receptor pre-mRNA editing and expression of the alpha subunit of the heterotrimeric G-protein G q.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2007, Feb-07, Volume: 27, Issue:6

    Topics: Age Factors; Animals; Anxiety, Separation; Body Weight; Depressive Disorder; Emotions; Environment;

2007
Effects of rearing condition on HPA axis response to fluoxetine and desipramine treatment over repeated social separations in young rhesus monkeys.
    Psychiatry research, 1998, Jun-15, Volume: 79, Issue:2

    Topics: Adrenocorticotropic Hormone; Analysis of Variance; Animals; Antidepressive Agents; Anxiety, Separati

1998
Biogenic amine activity in response to fluoxetine and desipramine in differentially reared rhesus monkeys.
    Biological psychiatry, 1999, Jul-15, Volume: 46, Issue:2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animal Husbandry; Animals; Antidepressive Agents, Second-Generation;

1999
Fluoxetine enhances cell proliferation and prevents apoptosis in dentate gyrus of maternally separated rats.
    Molecular psychiatry, 2001, Volume: 6, Issue:6

    Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety, Separation; Apoptosis; Cell Division; De

2001
Fluoxetine and suicidal ideation.
    Journal of the American Academy of Child and Adolescent Psychiatry, 1991, Volume: 30, Issue:4

    Topics: Adolescent; Anxiety, Separation; Dose-Response Relationship, Drug; Fluoxetine; Humans; Male; Obsessi

1991